It is accepted that there is a raised risk of birth defects in infants born to mothers with diabetes. It is not known if the risk rises with lack of diabetic control, as reflected by maternal glycated haemoglobin (HbA1c) levels.
To investigate such an association, Swedish researchers reviewed cardiac defects in 2500 infants born to mothers with type 1 diabetes and related the risk to HbA1c levels around the time of conception (Ludvigsson et al. BMJ 2018; 362:k2638) . The rate of major defects rose with increasing levels of HbA1c (Figure 1 ).
In the general population, the incidence of other (non-cardiac) major defects was 18 per 1000 and the risk of these abnormalities was not raised for mothers with type 1 diabetes, irrespective of their periconception HbA1c levels. Only live births were counted; therefore, it is possible that other defects such as those associated with neural tube development were identified and these pregnancies terminated, thus not included. The data also do not include mothers with type 2 diabetes.
The authors speculate that hyperglycaemia may influence the expression of genes that are responsible for the early development of the heart or work through oxidative stress leading to mitochondrial dysfunction and apoptosis. Either way, this large study confirms the raised risk of cardiac defects associated with poor diabetic control around the time of conception and organogenesis.
Antenatal detection of cardiac abnormalities
As antenatal care -especially ultrasound screening -becomes more sophisticated, many advantages accrue and some dilemmas are raised. In Denmark, universal free-of-charge prenatal ultrasound screening has been offered to all women for the past 15 years, and 95% of the population avail themselves of this option. The technology has improved over time and so has the training, scanning skill and organisation of ultrasound services so most serious abnormalities are now detected antenatally. A report has been published on the discovery and management of congenital heart disease and how outcomes have been affected (Lytzen et al. JAMA Cardiology 2018; 3:829-37) . The range of cardiac defects that can be diagnosed by ultrasound varies from minor to major and from incidental to incompatible with extrauterine existence. Over the time of the study, the occurrence of all congenital heart disease did not change, but the frequency of major abnormalities (which constitute one-fifth of all diagnoses) fell from 22 to 14 per 1000 live births.
The investigators report that with increasing expertise and central referring of cases, better care can be offered -for example, surgical repair in specialised centres or termination of pregnancy in severe abnormalities so parents can be given options and prepare themselves for future decisions. More than two-thirds of major defects are diagnosed in utero and 40% of such pregnancies terminated. Survival rates and quality of life are better when abnormalities are discovered antenatally rather than postnatally.
Dilemmas are as follows: Universal free scanning services are only available in developed countries with organised and efficient health services;
Some major cardiac defects are surgically correctable, but these procedures may be financially and psychologically demanding, making decisions difficult;
Termination of pregnancy or preparation for anticipated paediatric palliative care can create moral, religious and social quandaries; There may be conscious or unconscious pressure brought to bear on parents that call for high levels of patient care and considerable empathy; and Most countries have more advanced services obtainable outside standard care and disparities of health care commensurate with wealth are brought into sharp relief with this 'technology at a price' (Kon JAMA Cardiology 2018;3:837-8).
Is carbetocin the new oxytocin?
Intramuscular oxytocin is the standard drug for the prevention of postpartum haemorrhage (PPH) following vaginal delivery. However, oxytocin is heatunstable and needs to be transported and stored below 20°C, which can be problematic in warm countries where facilities are limited. These are often the countries with the highest rates of PPH so uterotonic agents not requiring cold-chain availability would be an advantage.
Carbetocin is a heat-stable, synthetic oxytocic agent with a biological action NEJM 2018; 379:743-52) . PPH of at least 500 ml of blood was recorded in 14.5% in the carbetocin group and 14.4% in the oxytocin group. The frequency of blood loss of more than 1 litre was close to 1.5% in both groups. The necessity of additional uterotonics and adverse effects did not differ.
These results are promising in that the oxytocin used was correctly transported and stored so it should have been optimally effective. This is not the case in all clinical situations. Costs will have to be assessed, but there will be financial advantages in not having to provide refrigeration for carbetocin.
Will this pragmatic trial be carried forward with the assistance of the philanthropic initiatives of the sponsoring pharmaceutical companies? Will carbetocin be made available at competitive prices and make significant inroads into PPH statistics and result in saving women's lives?
Termination of pregnancy at home
Medical termination of pregnancy (TOP) is now the method of choice in women seeking to end an early pregnancy. As the doses of mifepristone and misoprostol are standardised and the routes of administration clarified, the timing and place of using the uterotonic agents are coming under scrutiny.
With the availability of pregnancy tests over-the-counter and the widespread use of ultrasound, pregnancies are diagnosed early and dated accurately so decisions can be made about TOP well before the end of the first trimester. Medical TOP up to 8 weeks' gestation is efficient, with over 90% of women not requiring further intervention.
Mifepristone (200 mg orally) is followed 1-2 days later by misoprostol (800 lg sublingually or vaginally), and in some countries, one or both drugs are given in clinic settings. There are different opinions and regulations about whether the misoprostol can/should be taken at home and this is exercising the minds of administrators in the UK at present. The arguments in favour of asking women to return to the clinic to receive and take misoprostol are mainly historical as there are no differences in efficacy on the basis of where the drug is given. The points in favour of home administration are that the woman can initiate events at a time that suits her, at a place of her convenience, surrounded by her choice of support and with privacy.
It has been known for several years that women prefer home administration (Ngo et al. Bull World Health Organ 2011; 89:360-70) . It is as safe and as effective as the clinic option, with greater patient dignity. Maybe it is time for England and many other countries to change the rules to allow TOP at home for the patient's sake (Thornton BMJ 2018;361:k2879).
Vitamin D and cancer risk
There have been conflicting reports about vitamin D supplementation and the risk of cancer. The lack of consistent direction from research may be due to defining the normal range of 25-hydroxyvitamin D levels, dosages, frequency and rate of administration, co-supplements (notably calcium), or the selection of people for trial participation.
Most trials find that vitamin D supplementation does not outperform placebo for any outcomes, and the latest comprehensive data from New Zealand are no different (Scragg et al. JAMA Oncol https:// doi.org/10.1001/jamaoncol.2018.2178). The researchers gave over 5000 participants large doses of vitamin D (100 000 IU orally monthly) or placebo for longer than 3 years. They were healthy, community-dwelling adults, and the outcome measured was the development of any cancer. Those receiving the active intervention raised their serum 25-hydroxyvitamin D levels, but their overall cancer risk (6.5%) was similar to that of those receiving inert therapy (6.4%).
Cannabis and pregnancy
The opioid epidemic in the USA has caused people to look for other methods of pain relief and marijuana use is one option being suggested. Marijuana is being decriminalised in many states, and the perception is that it is a relatively harmless alternative analgesic. Its consumption is increasing in the general population, with the latest records showing 4% of pregnant women using it.
The main psychoactive component is D9-tetrahydrocannabinol, which readily crosses the placenta. Its presence in the developing fetal brain affects neurotransmitter systems and their maturation, which in turn are related to reward/stress areas of the brain. These changes have the potential to adversely affect infant behaviour and development as late as teenage years. Examples are arousal and motor difficulties at birth through to childhood impairment of sleep and memory plus aggressive tendencies (Jansson et al. JAMA 2018; 320:545-6.) .
Birth cohort studies have demonstrated a link between parental cannabis use and psychotic symptoms in their offspring at the age of 10 years. Whether the association is causal for intrauterine or postnatal environmental use is unclear, but it seems its use 'unmasks' psychotic vulnerability (Bolhuis et al. Schizophrenia Bulletin 2018;44:S231-2). Cannabinoid ingestion in pregnancy is not safe and may have genetic effects that are transgenerational, so long-term follow-up will be required to document other adverse outcomes.
Other issues that arise are as follows: Cannabinoids are addictive and addicted pregnant women are at risk of intoxication, withdrawal, impaired judgement, attention distraction and lack of coordination, all of which can impede self or infant care.
Cannabis use is often associated with other drugs such as alcohol, nicotine and narcotics.
Cannabinoids are present in breast milk and their effect on the infant is unknown.
If marijuana is smoked, the potential for lung and cardiovascular disease is present together with pregnancy complications and fetal jeopardy.
The message from the medical profession should be clear and consistentthat marijuana use is detrimental to mother and fetus.
Athol Kent
New reports and guidelines 2018 final report: Results of a five-year partnership to reduce maternal and newborn mortality This final report, from the Saving Mothers, Giving Life public-private partnership, presents the results of a programme that aimed to reduce maternal and newborn mortality across subSaharan Africa. The report presents key data from Uganda, where the maternal mortality ratio is reported to have fallen by 44% over 5 years; from Zambia, where the ratio fell by 41% in 5 years; and from Nigeria, where the ratio fell by 28% in 2 years. The partnership reports that the quality of care that women received during pregnancy and childbirth also improved, but that efforts to improve newborn health were less successful. The report highlights aspects of the programme including a systems approach, measuring success, public-private partnership and strengthening the whole health system. The programme used the three-delay model to address the main factors responsible for women not receiving life-saving care (delays in the decision to seek care, reaching care and receiving medically appropriate quality care), and the report uses stories to outline the key aspects. The report also includes an innovation spotlight and discusses matters relating to return on investment in terms of health service delivery, health workforce, health information systems, access to essential medicines, health systems financing and leadership and governance.
Opioid use disorder documented at delivery hospitalisation -USA,
1999-2014
This Morbidity and Mortality Weekly Report produced by the Centers for Disease Control and Prevention in the USA is the first multistate analysis presenting data on opioid use by pregnant women, including prescription opioids, heroin and fentanyl. The report, which is based on hospital discharge data from the 1999-2014 Healthcare Cost and Utilization Project, discusses US national and state-specific trends in opioid use disorder in pregnant women which was documented at delivery. The paper states that the prevalence of opioid use disorder in pregnant women has more than quadrupled during 1999-2014 and that increasing trends are seen for all 28 states with at least 3 consecutive years of available data. The lowest average annual rate increase is reported in California, with the highest increases reported in Maine, New Mexico, Vermont, and West Virginia. The report aims to help US states to monitor opioid use disorder at delivery and highlight the need for increased prevention, monitoring and treatment of opioid use disorder among reproductive-aged and pregnant women.
Toolkit for research and development of paediatric antiretroviral drugs and formulations
This toolkit, developed by the HIV Department at the World Health Organization (WHO) and the WHO Paediatric Antiretroviral Working Group, highlights challenges and potential solutions to promote and support antiretroviral drug formulation research and development specifically for infants, children, adolescents and pregnant and breastfeeding women. The toolkit introduction states that in 2016, around 2.1 million children and 17.8 million women were living with HIV, but antiretroviral drug formulations specifically for these populations, including pregnant and breastfeeding women, remain limited. Available through the Global Health Training Centre, the toolkit consists of ten modules covering trial design, pharmacokinetic modelling, pregnant and breastfeeding women, co-infections, acceptability, community engagement, target product profile, product commercialisation, regulatory filing and pharmacovigilance. The developers state that despite a specific focus on HIV drug development, it is hoped that the principles and support outlined in this toolkit could be applied to the research and development process of other medications relevant to children and pregnant women.
Clinical guidelines updates

US Preventive Services Task Force
The following guideline is now available at www.uspreventiveservicestaskforce.org
Final Recommendation Statement: Syphilis Infection in Pregnant Women: Screening
Faculty of Sexual and Reproductive Healthcare (FSRH)
The following guidelines are now available at www.fsrh.org FSRH/RCOG statement on buffer zones outside abortion clinics CEU response to published study on maternal use of hormonal contraception and risk of childhood leukaemia
American College of Obstetricians and Gynecologists (ACOG)
The following guidelines are now available at www.acog.org quality in the provision of health services and how essential quality care is to enable successful delivery of universal health coverage. The paper covers striving for quality in healthcare services, the global state of healthcare quality, building quality into the foundations of health systems and understanding levers to improve quality (including case studies from Ethiopia, Sudan, Mexico, and Canada). Chapter 6 provides a call to action to countries to ensure quality is built in to all efforts to improve health systems and implement universal health coverage. Box 6.1 highlights high-level actions by key constituencies for quality in health care, including those for governments, health systems, citizens and patients, and health workers. The annex outlines information and research on selected interventions related to improvement including clinical governance, adverse event reporting, health literacy, clinical audit and feedback, medicines regulation, shared decisionmaking, safety checklists and protocols.
Innovations and patents
Patent applications US2018217154 (A1) Compositions and methods for diagnosing and treating endometriosis-related infertility. This patent application relates to methods for the diagnosis of endometriosis. Specifically, it proposes measuring levels of at least one enzyme that synthesises or metabolises sphingosine-1-phosphate and/or measuring levels of at least one sphingosine-1-phosphate receptor in a peripheral blood leucocyte sample. The levels are then compared with a sample obtained from a woman without the disease, with elevated levels indicating presence of endometriosis.
This application claims benefit of priority to US Provisional Application Serial No. 62/194,959, filed July 21, 2015.
Yeung P Jr, Salvemini D. 2 August 2018.
US2018214119 (A1) Ultrasound and photoacoustic systems and methods for fetal brain assessment during delivery. This patent application relates to the development of a system using ultrasound and photoacoustic systems for multi-parametric, non-invasive, and real-time assessment of fetal brain oxygen consumption during labour and vaginal delivery.
The present specification claims priority to US Provisional App. No. 62/ 451,392, filed 27 January 2017, and entitled 'Ultrasound and photoacoustic systems and methods for fetal brain assessment during delivery'. WO2018138090 (A1) Diet composition for the prevention and/or the treatment of endometrial hyperplasia. This patent application relates to the development of a diet composition for the prevention and/or the treatment of endometrial hyperplasia. Specifically, the diet comprises a fasting mimicking diet providing <50% of the normal calorie intake and with both protein and sugar restricted for 2-10 days followed by a re-feeding diet providing 60-100% of the normal calorie intake lasting from 7 to 85 days. The fasting mimicking diet and the re-feeding diet are intended to be administered for multiple cycles.
Nencioni A, Caffa I, Becherini P, Longo V. 2 August 2018.
Legal matters Uterus transplantation in Lebanon
Doctors in Lebanon, working with a Swedish medical team, have recently completed the first ever uterus transplant in the country. The woman receiving the uterus had previously been diagnosed with uterine factor infertility. The Lebanese medical team are hoping that their transplant procedure will be the first in the Middle East to result in a live birth. Surrogacy is forbidden in many Islamic countries, so for the many women in the Middle East with uterine factor infertility, uterus transplantation could be the only way to achieve genetic motherhood.
Source: www.bionews.org.uk
Canada judge rules frozen embryo is 'property'
A court in Ontario, Canada, has ruled that an embryo is to be regarded as 'property'. The case centres on a divorced couple who had previously undergone fertility treatment during which four embryos were created that were not genetically related to either member of the couple. Two embryos were not viable, one was carried successfully and the ex-wife wished to establish another pregnancy using the last embryo. There is no law in Canada covering the disposal of embryos when they are not genetically related to either of the couple. The Ontario clinic agreement stated that if the couple divorced the patient's wishes would be respected regarding the embryos, with the patient in this case being named as the wife. Source: www.bionews.org.uk
Clinical trials
Clinicians keen to keep up to date regarding clinical studies that are currently recruiting may find the following informative.
Efficacy of cryoablation of abdominal wall endometriosis (CRYOENDOMET) 
